AI-Enhanced Mammograms: A New Frontier in Women's Heart Health

Mar 9, 2026, 2:44 AM

Hover over text to view sources

Recent research suggests that artificial intelligence (AI) could revolutionize the way mammograms are used by not only detecting breast cancer but also assessing the risk of heart disease in women. This dual-purpose approach leverages existing breast imaging technology to identify cardiovascular issues, addressing a critical gap in women's health assessments.

Using AI to analyze mammogram scans provides a novel method for evaluating cardiovascular risk by measuring calcium deposits in breast arteries. A study published in the European Heart Journal revealed that increased calcium visibility in these arteries correlates with a higher risk of severe cardiovascular events, such as heart attacks and strokes, especially in women under 50 who are typically considered low-risk.

In this landmark study, researchers analyzed data from 123,762 women aged 40 to 79 who underwent routine mammograms. They found that women with mild breast arterial calcification (BAC) had a 30% higher risk of experiencing major cardiovascular events compared to those with no BAC. This risk escalated to approximately three times for women with severe BAC.

The research highlights the significance of this screening, suggesting that a mammogram could serve as a vital tool for heart health discussions between patients and healthcare providers. "For women, a mammogram you're already having could also provide important information about your heart health," said Dr Hari Trivedi, the study's lead author.

Beyond the US, similar advancements are occurring globally. Researchers at The George Institute for Global Health have developed a machine learning model that predicts heart disease risk using mammographic features and age, achieving accuracy comparable to traditional cardiovascular risk calculators. This innovative model emphasizes the need for integrated approaches to cardiovascular screening, particularly as many women remain unaware of their heart disease risk factors.

Despite the potential benefits, some experts urge caution. Critics point out that while breast arterial calcification is linked to heart disease, it does not provide a complete picture of a woman's cardiovascular health. For instance, many cardiovascular events occur in women without visible BAC. As Dr Sadiya Khan, a preventive cardiologist, noted, relying solely on BAC data may not deliver conclusive heart disease risk assessments.

However, the integration of AI in mammography could lead to more widespread screening and early intervention. Approximately 40 million mammograms are performed annually in the US, and many practices are beginning to offer AI-enhanced analyses to identify calcifications that may indicate heart disease risk. For example, the Lynn Women's Health and Wellness Institute in Florida has implemented routine screenings for BAC, ensuring women are informed about their cardiovascular health.

Moreover, collaborations between companies like iCAD and Solis Mammography aim to further enhance the use of AI in evaluating cardiovascular risk through mammography. This partnership seeks to quantify BAC and develop a robust screening tool that could potentially identify millions of women at risk for heart disease.

As these technologies continue to evolve, the hope is that they will lead to improved preventive care for women, who are often underdiagnosed for cardiovascular conditions. Given that cardiovascular disease is the leading cause of death among women, these advancements could significantly impact public health outcomes.

In conclusion, the intersection of AI technology and mammography presents a promising avenue for enhancing women's health screening. With ongoing research and development, the potential to transform routine breast scans into comprehensive health assessments is on the horizon, paving the way for better prevention and treatment strategies for heart disease in women.

FDA's Updated Criteria for Breakthrough Device Designation

The FDA has revised its guidelines for the Breakthrough Devices Program, emphasizing the importance of health equity and accessibility in device designation. This evolution reflects a broader understanding of how medical technologies can address healthcare disparities while ensuring patient safety and efficacy.

Rocket Pharmaceuticals Secures FDA Approval for Kresladi Therapy

Rocket Pharmaceuticals has received accelerated FDA approval for Kresladi, a gene therapy for severe leukocyte adhesion deficiency-I (LAD-I), a rare genetic disorder affecting children's immune systems. This milestone not only offers hope for affected families but also positions Rocket for future growth as it prepares to conduct necessary post-marketing trials.

Regeneron Science Talent Search 2026 Awards Over $1.8 Million to Young Innovators

The 2026 Regeneron Science Talent Search honored top high school scientists, awarding more than $1.8 million in prizes. Connor Hill won the top award for his innovative work in computational mathematics, while other finalists explored fields such as neural science and cancer treatment.

UVA Health Joins Global Effort to Innovate Pediatric Cancer Treatments

UVA Health researchers have partnered with an international consortium to develop advanced treatments for childhood cancers. This collaboration aims to address the lack of investment in pediatric drug development and improve outcomes for patients facing aggressive forms of cancer.

Study Reveals ChatGPT Health 'Under-Triaged' Medical Emergencies

A recent study published in Nature Medicine has revealed that ChatGPT Health, OpenAI's specialized medical chatbot, under-triaged over half of medical emergencies. The research highlights significant flaws in the AI's ability to assess urgent medical situations, potentially putting users at risk.